Posted on September 25, 2018
This is a study by CAMH, the leading mental health research hospital in Canada. Learn more about what's involved in participating in a study at CAMH Research Connect.
CAMH is part of an international study exploring a potential new treatment for agitation in people who have Alzheimer’s disease.
Agitation affects up to 60% of people with Alzheimer’s disease. Symptoms can include emotional distress, aggression, and impulsiveness. People who experience agitation may get anxious or upset easily. They might be restless, unable to sleep or pace back and forth. These symptoms can be challenging for people experiencing them and their family and friends.
Treatment options for agitation in Alzheimer’s disease are limited. The S-CitAD study is a clinical trial sponsored by the National Institute on Aging (NIA) in the U.S. The study is examining if a prescription medication called escitalopram combined with in-person therapy can help reduce agitation. The therapy involves meeting with a trained health care professional and discussing activities, techniques and strategies that can help improve your well-being and day-to-day functioning.
We are looking for participants who:
- have a diagnosis of Alzheimer’s dementia
- are experiencing symptoms of agitation
- have an available caregiver who spends at least several hours a week with the participant, supervises his/her care, and is willing to accompany the participant to study visits and participate in the study themselves
- are not currently living in a skilled nursing or Long-Term Acute Care (LTAC) facility
The study is designed to last 24 weeks, with treatment for 12 weeks, followed by a 12-week safety follow-up. Participants will be required to come in with their caregiver for a total of 6 clinic visits at the Centre for Addiction and Mental Health. The rest of the follow-up will be done over the phone.
To learn more or ask about joining our study, please call 416-583-1350 or email email@example.com.
You can also find our study details in our CAMH study listing.
CAMH REB number: IRB00148995